Global Travel Industry Embracing Autonomous UVD Robots
23.9.2020 16:02:00 EEST | Business Wire | Press release
With the latest forecast by the U.S. Travel Association by Tourism Economics predicting $505 billion in losses globally through the end of 2020, UVD Robots announced its autonomous disinfecting robot is being increasingly deployed within hotels, railways, and airports globally. UVD Robots’ mobile, fully autonomous robot integrates UVC light and a large number of disinfection-specialized apps to disinfect against viruses and bacteria not only on surfaces, but the air as well, providing a fully comprehensive infection control and prevention solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200923005177/en/
“Right now it’s critical for the hospitality industry to not only enhance how we protect travelers but also provide them with reassurance that we’re taking every possible step from check-in to check-out,” said Trish Berry, General Manager, YOTEL Boston. An extension of YOTEL’s operation #SmartStay safety measures, the UVD Robot, named ‘Vi-YO-Let’, will offer an even deeper level of disinfection throughout high-touch public spaces and select cabins at YOTEL Boston. Photo credit: YOTEL Boston.
“As the travel and hospitality industry looks to bring travelers back, they are working to meet new and heightened expectations for safety and cleanliness in order to build trust,” said Per Juul Nielsen, CEO of UVD Robots. “Because our UVD Robots are simple, safe and effective, we are working with an increasing number of hotels, airports, railways and others to bring hospital-grade disinfection solutions to these facilities. We couldn’t be more thrilled than to play a role in the recovery of this industry.”
Examples include:
- YOTEL Boston announced it has implemented the UVD Robots technology to clean select cabins when vacant with all high-touch public spaces also being disinfected upon closing.
- The Clarion Hotel & Congress Copenhagen Airport is applying UVD Robots to disinfect conference rooms and public areas.
- The Gerald R. Ford International Airport (GRR) is using UVD Robots to disinfect bathrooms, baggage claim areas, passenger checkpoints, TSA areas, and more after hours.
- UVD Robots has been operational at Heathrow Airport in London for several months.
- St. Pancras International railway station in London is deploying UVD Robots to disinfect washrooms at the stations.
Several additional projects are also currently being carried out in the travel industry within the Middle East, including the Hamad International Airport in Qatar.
About UVD Robots & Blue Ocean Robotics
UVD Robots is a subsidiary of one of the world's leading groups in the development of professional service robots, Blue Ocean Robotics, that also includes subsidiaries like GoBe Robots, PTR Robots and Mink Robots. Blue Ocean Robotics is headquartered in Europe’s “robot capital” Odense in Denmark.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200923005177/en/
Contact information
Merima Cikotic
Blue Ocean Robotics
mc@blue-ocean-robotics.com
+45 71-99-56-06
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom